Sun Pharma submits $13 billion binding offer for Organon acquisition. Indian pharmaceutical giant, led by Dilip Shanghvi, aims to transform itself into a global branded drugmaker through this strategic move. The all-cash bid is fully financed by JP Morgan, MUFG, and Citi, competing against Swedish buyout firm EQT and German drugmaker Gruenthal. Sun's market valuation stands at $42.8 billion, while the target company carries $8.64 billion in debt. If successful, Organon will merge with Sun, though shareholders won't receive Sun shares. This acquisition represents Sun Pharma's largest strategic bet to expand beyond generics into innovative pharmaceutical development and strengthen its global presence.
Post from MarketNews_en
Log in to interact with content.